Edition:
United States

Immuron Ltd (IMC.AX)

IMC.AX on Australia Stock Exchange

0.19AUD
22 Sep 2017
Change (% chg)

$0.01 (+8.57%)
Prev Close
$0.17
Open
$0.17
Day's High
$0.19
Day's Low
$0.17
Volume
112,400
Avg. Vol
255,774
52-wk High
$0.70
52-wk Low
$0.16

Chart for

About

Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products... (more)
No analyst recommendations are available for .

Overall

Beta: -0.81
Market Cap(Mil.): $22.83
Shares Outstanding(Mil.): 130.44
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.33
EPS (TTM): -- -- --
ROI: -- 15.11 14.66
ROE: -- 16.37 13.99

BRIEF-Immuron posts FY net loss for period attributable to members $6.8 mln

* FY net loss for period attributable to members $6.8 million versus loss of $5.6 million Source text for Eikon: Further company coverage:

Aug 31 2017

BRIEF-Immuron says approved to commence clinical study in C.Difficile infection

* Immuron approved to commence clinical study in c.difficile infection (cdi)

Aug 09 2017

BRIEF-Immuron Ltd's ADSs open at $9.25 in debut vs IPO price of $10/ADS

* Immuron Ltd's American Depositary Shares open at $9.25 in debut on the NASDAQ versus IPO price of $10.00 ‍​per ADS Further company coverage:

Jun 09 2017

BRIEF-Immuron requests trading halt

* Requests trading halt ‍as company evaluates a proposed capital transaction​ Source text for Eikon: Further company coverage:

Jun 07 2017

BRIEF-Immuron secures $1.5 mln research and development cash advance loan funding

* Immuron secures $1.5 mln research and development cash advance loan funding Source text for Eikon: Further company coverage:

May 31 2017

BRIEF-Immuron Ltd seeks trading halt

* Seeks trading halt pending an announcement to market in respect of a proposed us nasdaq initial public offer Source text for Eikon: Further company coverage:

May 29 2017

BRIEF-Immuron Ltd sees U.S. IPO priced at $10-$12.50 per ADS

* Immuron Ltd sees U.S. IPO priced between $10.00 and $12.50 per ads and $0.01 per warrant - sec filing

May 24 2017

BRIEF-Immuron expands agreement with U.S. army

* immuron expands agreement with us army to include 3 shigella therapeutics

May 16 2017

BRIEF-Immuron offering 416,667 ads and warrants to purchase 208,334 ads

* Says offering 416,667 ads and warrants to purchase 208,334 ads

May 08 2017

BRIEF-Immuron ltd announces positive results of IMM-124E in Acute Colitis research studies

* Immuron Ltd - announces positive results of imm-124e in acute colitis research studies

Apr 18 2017

Earnings vs. Estimates